MA43717A - Anticorps anti-tnf et fragments fonctionnels de ceux-ci - Google Patents

Anticorps anti-tnf et fragments fonctionnels de ceux-ci

Info

Publication number
MA43717A
MA43717A MA043717A MA43717A MA43717A MA 43717 A MA43717 A MA 43717A MA 043717 A MA043717 A MA 043717A MA 43717 A MA43717 A MA 43717A MA 43717 A MA43717 A MA 43717A
Authority
MA
Morocco
Prior art keywords
functional fragments
tnf antibodies
tnf
antibodies
fragments
Prior art date
Application number
MA043717A
Other languages
English (en)
Other versions
MA43717B1 (fr
Inventor
Esther Maria Furrer
Tea Gunde
Sebastian Meyer
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of MA43717A publication Critical patent/MA43717A/fr
Publication of MA43717B1 publication Critical patent/MA43717B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA43717A 2016-03-17 2017-03-16 Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci MA43717B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16160907.8A EP3219726B1 (fr) 2016-03-17 2016-03-17 Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci
PCT/EP2017/056237 WO2017158092A1 (fr) 2016-03-17 2017-03-16 Anticorps anti-tnfα et fragments fonctionnels de ceux-ci

Publications (2)

Publication Number Publication Date
MA43717A true MA43717A (fr) 2018-11-28
MA43717B1 MA43717B1 (fr) 2023-11-30

Family

ID=55542576

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43717A MA43717B1 (fr) 2016-03-17 2017-03-16 Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci

Country Status (40)

Country Link
US (3) US11459383B2 (fr)
EP (3) EP3219726B1 (fr)
JP (2) JP7129398B2 (fr)
KR (2) KR102470235B1 (fr)
CN (1) CN109071650B (fr)
AR (1) AR107917A1 (fr)
AU (2) AU2017235387B2 (fr)
CA (1) CA3011784C (fr)
CL (1) CL2018002649A1 (fr)
CO (1) CO2018009783A2 (fr)
CR (1) CR20180448A (fr)
CY (1) CY1123784T1 (fr)
DK (2) DK3219726T3 (fr)
EA (1) EA039760B1 (fr)
ES (3) ES2836349T3 (fr)
FI (1) FI3430043T3 (fr)
GE (2) GEP20217307B (fr)
HR (2) HRP20231464T1 (fr)
HU (2) HUE052773T2 (fr)
IL (2) IL261031B2 (fr)
JO (2) JOP20170064B1 (fr)
LT (2) LT3219726T (fr)
MA (1) MA43717B1 (fr)
MD (1) MD3430043T2 (fr)
MX (1) MX2018011258A (fr)
MY (1) MY194041A (fr)
PH (1) PH12018501907A1 (fr)
PL (2) PL3219726T3 (fr)
PT (2) PT3219726T (fr)
RS (2) RS61374B1 (fr)
SA (1) SA518400027B1 (fr)
SG (1) SG11201807062RA (fr)
SI (2) SI3219726T1 (fr)
SM (2) SMT202000706T1 (fr)
TN (1) TN2018000298A1 (fr)
TW (2) TWI784945B (fr)
UA (1) UA128715C2 (fr)
UY (1) UY37157A (fr)
WO (1) WO2017158092A1 (fr)
ZA (5) ZA201805919B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3219727B1 (fr) 2016-03-17 2020-12-16 Tillotts Pharma AG Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci
EA039323B1 (ru) 2016-03-17 2022-01-13 Нумаб Инновейшн Аг Антитела к фно и их функциональные фрагменты
EA039201B1 (ru) 2016-03-17 2021-12-16 Нумаб Инновейшн Аг Антитела к фно и их функциональные фрагменты
PT3219726T (pt) * 2016-03-17 2020-12-15 Tillotts Pharma Ag Alfa-anticorpos anti-tnf e fragmentos funcionais dos mesmos
ES2978167T3 (es) * 2017-09-19 2024-09-06 Tillotts Pharma Ag Variantes de anticuerpos
EP3456738B1 (fr) * 2017-09-19 2024-07-17 Tillotts Pharma Ag Variantes d'anticorps
SI3456736T1 (sl) * 2017-09-19 2021-06-30 Tillotts Pharma Ag Variante protitelesa
WO2020114616A1 (fr) * 2018-12-07 2020-06-11 Tillotts Pharma Ag Traitement topique d'une diarrhée, d'une colite ou d'une entérocolite induite par un inhibiteur de point de contrôle immunitaire au moyen d'anticorps et de fragments de ceux-ci

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP1690935A3 (fr) 1990-01-12 2008-07-30 Abgenix, Inc. Génération d'anticorps xenogéniques
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
NO309690B1 (no) 1995-01-23 2001-03-12 Western Atlas Int Inc Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
CA2219361C (fr) 1995-04-27 2012-02-28 Abgenix, Inc. Anticorps humains derives d'une xenosouris immunisee
WO1996034096A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
ATE239041T1 (de) * 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (fr) 1996-12-03 2008-09-24 Amgen Fremont Inc. Mammifères transgéniques disposant d'un loci ig comprenant plusieurs régions vh et vk et anticorps produits à partir de ceux-ci
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
US7431927B2 (en) 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
EP1891110A2 (fr) 2005-06-07 2008-02-27 Esbatech AG ANTICORPS STABLES ET SOLUBLES INHIBANT LE TNF-alpha
PL2307458T3 (pl) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
RU2653753C1 (ru) 2008-06-25 2018-05-14 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα
MX2011000009A (es) 2008-07-10 2011-08-15 Esbatech Alcon Biomed Res Unit Metodos y composiciones para la administracion mejorada de macromoleculas.
MX2012011629A (es) * 2010-04-07 2013-03-05 Abbvie Inc Proteinas de union a tnf-alfa.
AU2011277983C1 (en) * 2010-07-16 2016-09-29 Ablynx Nv Modified single domain antigen binding molecules and uses thereof
CN102443063B (zh) * 2010-09-30 2013-10-23 成都康弘生物科技有限公司 抗TNFα的人源化Fab和人源化抗体及其用途
HK1218549A1 (zh) 2013-06-26 2017-02-24 Numab Therapeutics AG 新型抗体框架
CA2924520C (fr) * 2013-11-01 2023-09-26 Ibc Pharmaceuticals, Inc. Anticorps bispecifiques qui neutralisent a la fois tnf-alpha et il-6 : nouvel agent therapeutique pour traiter une maladie auto-immune
US10233238B2 (en) * 2014-03-26 2019-03-19 Cell Medica Switzerland Ag TNF alpha antibody or fragment thereof and methods of use
EP3219727B1 (fr) 2016-03-17 2020-12-16 Tillotts Pharma AG Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci
PT3219726T (pt) * 2016-03-17 2020-12-15 Tillotts Pharma Ag Alfa-anticorpos anti-tnf e fragmentos funcionais dos mesmos
EA039323B1 (ru) 2016-03-17 2022-01-13 Нумаб Инновейшн Аг Антитела к фно и их функциональные фрагменты
EA039201B1 (ru) 2016-03-17 2021-12-16 Нумаб Инновейшн Аг Антитела к фно и их функциональные фрагменты
SI3456736T1 (sl) * 2017-09-19 2021-06-30 Tillotts Pharma Ag Variante protitelesa

Also Published As

Publication number Publication date
MX2018011258A (es) 2019-02-13
JOP20170064B1 (ar) 2021-08-17
ES3043897T3 (en) 2025-11-26
AU2017235387B2 (en) 2024-06-27
EA039760B1 (ru) 2022-03-10
US12209122B2 (en) 2025-01-28
KR20180120149A (ko) 2018-11-05
EA201891788A1 (ru) 2019-01-31
PH12018501907A1 (en) 2019-06-17
DK3430043T3 (da) 2023-11-27
MD3430043T2 (ro) 2024-02-29
EP3430043A1 (fr) 2019-01-23
SI3430043T1 (sl) 2024-01-31
HRP20210123T1 (hr) 2021-03-05
TWI829444B (zh) 2024-01-11
EP4275745A3 (fr) 2023-12-20
CN109071650B (zh) 2022-05-13
LT3219726T (lt) 2021-01-25
UA128715C2 (uk) 2024-10-09
AR107917A1 (es) 2018-06-28
ES2836349T3 (es) 2021-06-24
NZ745999A (en) 2024-08-30
ZA202108601B (en) 2022-03-30
TW202311288A (zh) 2023-03-16
JOP20210085A1 (ar) 2023-01-30
SI3219726T1 (sl) 2021-02-26
EP4275745B1 (fr) 2025-07-16
CY1123784T1 (el) 2022-05-27
BR112018016667A2 (pt) 2019-02-05
KR20220158877A (ko) 2022-12-01
IL261031B1 (en) 2025-09-01
SG11201807062RA (en) 2018-09-27
CR20180448A (es) 2019-01-25
IL322669A (en) 2025-10-01
ZA202108599B (en) 2022-03-30
DK3219726T3 (da) 2020-12-07
EP3430043B1 (fr) 2023-08-30
JP2022130407A (ja) 2022-09-06
SMT202000706T1 (it) 2021-01-05
TWI784945B (zh) 2022-12-01
PT3430043T (pt) 2023-11-23
IL261031B2 (en) 2026-01-01
ZA201805919B (en) 2024-12-18
US20230272059A1 (en) 2023-08-31
KR102470235B1 (ko) 2022-11-24
ZA202108602B (en) 2022-03-30
GEP20217307B (en) 2021-10-25
FI3430043T3 (fi) 2023-11-17
GEAP202114876A (en) 2021-05-13
HRP20231464T1 (hr) 2024-03-01
IL261031A (en) 2018-10-31
TW201739766A (zh) 2017-11-16
ZA202108600B (en) 2022-03-30
SA518400027B1 (ar) 2022-03-06
US20210198353A1 (en) 2021-07-01
TN2018000298A1 (en) 2020-01-16
PL3430043T3 (pl) 2024-03-11
AU2024219840A1 (en) 2024-10-10
CA3011784A1 (fr) 2017-09-21
JP7129398B2 (ja) 2022-09-01
PT3219726T (pt) 2020-12-15
US11459383B2 (en) 2022-10-04
CN109071650A (zh) 2018-12-21
DK3430043T5 (da) 2024-09-23
ES2963221T3 (es) 2024-03-26
SMT202300429T1 (it) 2024-01-10
HUE052773T2 (hu) 2021-05-28
WO2017158092A1 (fr) 2017-09-21
RS64830B1 (sr) 2023-12-29
CA3011784C (fr) 2024-04-23
JOP20210085B1 (ar) 2025-10-01
AU2017235387A1 (en) 2018-09-27
PL3219726T3 (pl) 2021-07-19
US12043663B2 (en) 2024-07-23
CO2018009783A2 (es) 2018-09-28
MY194041A (en) 2022-11-09
MA43717B1 (fr) 2023-11-30
HUE064238T2 (hu) 2024-02-28
CL2018002649A1 (es) 2018-11-09
EP4275745A2 (fr) 2023-11-15
EP3219726B1 (fr) 2020-12-02
RS61374B1 (sr) 2021-02-26
LT3430043T (lt) 2023-12-27
JP2019512268A (ja) 2019-05-16
EP3219726A1 (fr) 2017-09-20
UY37157A (es) 2017-10-31
US20230279091A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
IL304117A (en) Anti-pvrig antibodies and methods of use
LT3601358T (lt) Anti-trem2 antikūnai ir jų naudojimo metodai
IL286208A (en) Humanized influenza monoclonal antibodies and methods of use thereof
EP3626825A4 (fr) Anticorps anti-cdh6 et conjugué anticorps anti-cdh6-médicament
KR102162129B9 (ko) 항-갈렉틴-9 항체 및 이의 용도
MA46525A (fr) Anticorps anti-lag-3 et compositions
IL264528B1 (en) Fcrn antibodies and methods of use thereof
LT3383916T (lt) Antikūnai prieš cd73 ir jų panaudojimo būdai
PT3250610T (pt) Anticorpos de fcrn e métodos de utilização dos mesmos
IL263657A (en) Anti-c5 antibodies and methods of use
MA44659A (fr) Anticorps anti-tim-3 et compositions
PT3468990T (pt) Anticorpos anti-c5 e utilizações dos mesmos
MA55347A (fr) Anticorps anti-lag3 et fragments de fixation à l'antigène
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
EP3397276A4 (fr) Anticorps et conjugués de ceux-ci
IL254670A0 (en) Humanized anti-c1s antibodies and methods of use thereof
IL269074A (en) Anti-tigit antigen-binding proteins and methods of use thereof
PT3274370T (pt) Anticorpos anti-ceacam6 e utilizações dos mesmos
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
PT3215532T (pt) Anticorpos anti-tim3 e métodos de utilização
LT3525583T (lt) Anti-c1s antikūnai ir jų naudojimo būdai
LT3227311T (lt) Įterpiami variabilūs antikūnų fragmentai ir nkg2d ligandų modifikuoti a1-a2 domenai
EP3592386A4 (fr) Anticorps anti-c5 et leurs utilisations
LT3532499T (lt) Antikūnai prieš il-33 ir jų panaudojimas
IL271398A (en) Anti-l1-cam antibodies and uses thereof